According to Marketwatch, recent studies and clinical trials reveal data to back effectiveness of Cannabidiol “CBD” Hemp oil as a medical treatment, marijuana industry forecasted to exceed $8 billion in next four years:Earth Science Tech, Inc. ETST, +23.49% GW Pharmaceuticals plc GWPH, -4.52% CannaVest Corp. CANV, -9.33% INSYS Therapeutics, Inc. INSY, -2.76% and Vape Holdings, Inc. VAPE, -10.14%
Earth Science Tech, Inc. (otcqb:ETST), a unique biotechnology company focused on neutraceuticals, bioceuticals and dietary supplements, announced today that ETST has received an initial report from the Sponsored Research Agreement with the University of Central Oklahoma a public institution of higher education, showing the effects of its Hemp Oil Enriched with CBD-Cannabidiol (provided by Earth Science Tech, Inc.) on animal breast cancer cells and on normal cells.
ETST confirmed these preliminary results on its Hemp Oil Enriched with CBD-Cannabidiol and the update regarding the Grant and Study with the University of Central Oklahoma lead investigator Dr. Wei R. Chen have been received.
The results of this preliminary study indicate that with appropriate dose, in this case with its proprietary Hemp Oil Enriched with CBD-Cannabidiol dose, Hemp Oil Enriched with CBD-Cannabidiol can inhibit the proliferation of cancer cells more than that of normal cells. If Hemp Oil Enriched with CBD-Cannabidiol has the same effect in vivo, it may help with cancer patients. However, further experiments are needed to investigate the effects of Hemp Oil Enriched with CBD-Cannabidiol on different cells, particularly on immune cells. CEO of ETST, Harvey Katz, PhD declared: “Our unique position working within the Enhanced Industrial Hemp Oil with CBD field and relationship with the University has already made significant strides on how the Hemp Oil with CBD works. This is just the beginning”. These finding are already leading to a better and the science of unlocking the benefits of Hemp Oil with CBD and its true potential. The next testing with immune cells has already begun.
In other related sector news: GW Pharmaceuticals plc GWPH, -4.52% a biopharmaceutical company, together with its subsidiaries, is engaged in discovering, developing, and commercializing cannabinoid prescription medicines. The company operates through three segments: Sativex Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. On Wednesday, GWPH closed up 1.44% on over 1.1 million shares traded.
CannaVest Corp. (otcqb:CANV) a leading supplier of cannabidiol (CBD) based compounds and products, will be showcasing their range ofPlusCBD Oil™ and retail products in Booth #22023 at the SupplySide West trade show on October 6-10, 2014, in Las Vegas, Nevada. In its fifteenth year, the show is billed as the world’s largest expo gathering for ingredient suppliers and finished product manufacturers. This year, the expo will be showcasing CannaVest’s wide range of formulation-ready CBD products, and the Company will be participating in the CBD and the Hemp Revolution seminar, from 8:30 to 11:30 a.m. on October 10th to discuss the biochemical, scientific, medical and consumer applications of CBD.
INSYS Therapeutics, Inc. INSY, -2.76% was recently named the 2014 Arizona Bioscience Company of the Year by the Arizona Bioindustry Association (AZBio). In one of the hottest years for biotech IPOs in recent memory, Insys was the top performing IPO of 2013 with over 380% growth in shareholder value and a market cap in excess of $800 million at the end of the year. “When one of our Arizona bioscience companies achieves great success, it’s cause for celebration across the entire community,” shared AZBio president and CEO Joan Koerber-Walker. “While early stage investors and shareholders have definitely benefited from the work of the Insys team, the real winners here are the patients who will benefit from the products that Insys delivers today and is developing for the future.” Read more here: http://finance.yahoo.com/news/insys-therapeutics-inc-named-arizona-120000764.html
Vape Holdings, Inc. (otcqb:VAPE), a holding company focused on providing healthy, efficient, and sustainable vaporization products, has announced the newest line of products under the HIVE brand, HIVE GLASS, which is set to release on or before December 1, 2014. The HIVE GLASS line is precision made using state of the art manufacturing processes and techniques, and exclusively uses German Schott glass and fittings through all production phases. “We have been researching and developing our production glass line for many months now, with the help of our extremely dedicated and experienced team, as well as various industry experts and glass manufacturers. We have developed what we believe to be an affordable, very high quality product that is both aesthetically pleasing and highly functional. Our existing customer base and distribution network will be the catalyst for expanding our HIVE brand across all vertical markets.”